The Safety and Efficacy of Supraglottic Airway Use in Children

July 27, 2015 updated by: Narasimhan Jagannathan, Ann & Robert H Lurie Children's Hospital of Chicago
This purpose of this study is to determine the effectiveness, risk factors, and complications associated with use of supraglottic airway devices for primary airway maintenance during routine anesthesia in children.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

This study aims to understand the efficacy of supraglottic airway (SGA) use in children in a tertiary care Children's Hospital.

Observational data regarding the type of SGA, experience level of practitioner, placement technique, number of placement attempts or placement failure, device failure, and cause of any related peri-operative complications will be prospectively collected.

The data collected in this study will allow the investigators to assess the overall safety and efficacy of SGA use in various medical and surgical procedures performed under general anesthesia in children.

Study Type

Observational

Enrollment (Anticipated)

10000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Illinois
      • Chicago, Illinois, United States, 60611
        • Recruiting
        • Ann & Robert H. Lurie Children's Hospital of Chicago
        • Contact:
        • Principal Investigator:
          • Narasimhan Jagannathan, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

1 day to 18 years (Child, Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Pediatric patients undergoing anesthesia with use of a supraglottic airway device as primary means of oxygenation and ventilation.

Description

Inclusion Criteria:

  • Children undergoing anesthesia with use of a supraglottic airway device as a primary means of oxygenation & ventilation

Exclusion Criteria:

  • N/A

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Supraglottic Airway Device
Patients will receive a supraglottic airway device as a primary means of ventilation. The following devices may be used: LMA Unique, LMA ProSeal, LMA Supreme, LMA Flexible, Ambu Aura-I, Ambu Aura Once, Air-Q, I-Gel, or other supraglottic airway device. Choice of the device will be clinician dependent and based on the patients body weight per manufacturer guidelines
Device: Supraglottic Airway Device
Other Names:
  • LMA Supreme
  • LMA ProSeal
  • I-Gel
  • LMA Unique
  • LMA Flexible
  • Ambu Aura-i
  • Ambu Aura Once
  • Air-Q

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Supraglottic Airway Device Failure
Time Frame: participants will be followed for the duration of anesthesia and after surgery, an expected average of 12 hours
Occurrence and reason for supraglottic airway device failure (ie inadequate ventilation, laryngospasm, bronchospasm, etc) will be recorded in addition to conversion to tracheal intubation
participants will be followed for the duration of anesthesia and after surgery, an expected average of 12 hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Ease of Placement of Supraglottic Airway Device
Time Frame: participants will be followed for the duration of anesthesia and after surgery, an expected average of 12 hours
Ease of placement of supraglottic airway device ranging from 1 (easy) to 4 (difficult)
participants will be followed for the duration of anesthesia and after surgery, an expected average of 12 hours
Multiple Attempts to Place Supraglottic Airway Device
Time Frame: participants will be followed for the duration of anesthesia and after surgery, an expected average of 12 hours
change in device, placement method, and provider will be recorded
participants will be followed for the duration of anesthesia and after surgery, an expected average of 12 hours
Airway Maneuvers/interventions
Time Frame: participants will be followed for the duration of anesthesia and after surgery, an expected average of 12 hours
the number and type of airway maneuvers performed after device placement and during maintenance will be recorded
participants will be followed for the duration of anesthesia and after surgery, an expected average of 12 hours
Occurrence of Inadequate Ventilation
Time Frame: participants will be followed for the duration of anesthesia and after surgery, an expected average of 12 hours
cause and solution for inadequate ventilation will be recorded
participants will be followed for the duration of anesthesia and after surgery, an expected average of 12 hours
Intraoperative Complications
Time Frame: participants will be followed for the duration of anesthesia and after surgery, an expected average of 12 hours
Time period of complication (ie during device placement, maintenance, or removal) and cause of complication (ie. dental injury, light anesthesia, regurgitation, laryngospasm, bronchospasm, aspiration, etc.) will be recorded
participants will be followed for the duration of anesthesia and after surgery, an expected average of 12 hours
Postoperative Complications
Time Frame: participants will be followed for the duration of anesthesia and 24 hours postoperatively
Complications noted postoperatively relating to reflex activation of the airway, sore throat, or hoarseness
participants will be followed for the duration of anesthesia and 24 hours postoperatively

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Ann & Robert H Lurie Children's Hospital of Chicago

Investigators

  • Principal Investigator: Narasimhan Jagannathan, MD, Ann & Robert H. Lurie Children's Hospital of Chicago / Stanley Manne Research Institute

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2014

Primary Completion (Anticipated)

October 1, 2015

Study Completion (Anticipated)

October 1, 2015

Study Registration Dates

First Submitted

July 25, 2014

First Submitted That Met QC Criteria

July 25, 2014

First Posted (Estimate)

July 28, 2014

Study Record Updates

Last Update Posted (Estimate)

July 29, 2015

Last Update Submitted That Met QC Criteria

July 27, 2015

Last Verified

July 1, 2015

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • 2014-15832

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Supraglottic Airway Use in Children

Clinical Trials on Supraglottic Airway Device

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Argentina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe